Skip to main navigation Skip to search Skip to main content

PAK1 is a novel therapeutic target in tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the PI3K/AKT signaling regardless of EGFR mutation

  • De-Wei Wu
  • , Tzu-Chin Wu
  • , Chih-Yi Chen
  • , Huei Lee

Research output: Contribution to journal › Article › peer-review

40   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'PAK1 is a novel therapeutic target in tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the PI3K/AKT signaling regardless of EGFR mutation'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science